News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
98,315 Results
Type
Article (4132)
Company Profile (7)
Press Release (94176)
Section
Business (36824)
Career Advice (103)
Deals (5618)
Drug Delivery (12)
Drug Development (11587)
Employer Resources (10)
FDA (2222)
Job Trends (2499)
News (51685)
Policy (3901)
Tag
2027 BioMidwest Standard (1)
Academia (273)
Accelerated approval (17)
ADA (6)
Allergies (33)
Alliances (3604)
ALS (30)
Alzheimer's disease (215)
Antibody-drug conjugate (ADC) (132)
Approvals (2478)
Artificial intelligence (90)
ASCO (73)
Autoimmune disease (82)
Automation (6)
Bankruptcy (32)
Belgium (17)
Best Places to Work (2251)
BIO (13)
Biologics (14)
Biosimilars (54)
BioSpace Insights (13)
Biotechnology (7)
Bispecific (8)
Bladder cancer (76)
Brain cancer (15)
Breast cancer (221)
Cancer (1638)
Cardiovascular disease (115)
Career advice (88)
Career pathing (2)
CAR-T (51)
CDC (8)
CDMO (12)
Celiac Disease (3)
Cell therapy (129)
Cervical cancer (15)
Clinical research (11638)
Collaboration (266)
Commercialization (6)
Company closure (2)
Compensation (195)
Complete response letters (17)
COVID-19 (354)
CRISPR (15)
CRO (1)
C-suite (111)
Cystic fibrosis (19)
Data (2407)
Decentralized trials (1)
Denatured (1)
Depression (21)
Dermatology (60)
Diabetes (178)
Diagnostics (1026)
Digital health (8)
Diversity, equity & inclusion (3)
Drug discovery (54)
Drug pricing (19)
Drug shortages (1)
Duchenne muscular dystrophy (44)
Earnings (29546)
Editorial (5)
Employer branding (3)
Employer resources (9)
ESMO (140)
Events (14786)
Executive appointments (86)
Eye disease (6)
FDA (3279)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (3)
Frontotemporal dementia (9)
Funding (214)
Gene editing (23)
Generative AI (9)
Gene therapy (103)
GLP-1 (204)
Government (607)
Grass and pollen (3)
Guidances (271)
Healthcare (3011)
Hematology (44)
HIV (23)
Huntington's disease (11)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (28)
Immunology and inflammation (78)
Immuno-oncology (27)
Indications (78)
Infectious disease (429)
Inflammatory bowel disease (96)
Inflation Reduction Act (2)
Influenza (20)
Intellectual property (30)
Interviews (14)
IPO (3804)
IRA (2)
Job creations (375)
Job search strategy (75)
JPM (6)
Kidney cancer (7)
Kidney disease (32)
Labor market (26)
Layoffs (72)
Leadership (5)
Legal (681)
Licensing (11)
Liver cancer (18)
Longevity (6)
Lung cancer (274)
Lymphoma (148)
Machine learning (6)
Management (1)
Manufacturing (160)
Marketing (7)
MASH (46)
Medical affairs (2)
Medical device (2200)
Medtech (2241)
Mergers & acquisitions (2076)
Metabolic disorders (385)
mRNA (28)
Multiple sclerosis (69)
NASH (1)
Netherlands (2)
Neurodegenerative disease (70)
Neuropsychiatric disorders (12)
Neuroscience (512)
NextGen: Class of 2026 (711)
Non-profit (559)
Now hiring (7)
Obesity (172)
Opinion (25)
Ovarian cancer (54)
Pain (45)
Pancreatic cancer (75)
Parkinson's disease (61)
Partnered (3)
Patents (71)
Patient advocacy (1)
Patient recruitment (101)
Patient selection (10)
Peanut (12)
People (3844)
Peptides (6)
Pharmaceutical (5)
Pharmacy benefit managers (7)
Phase 1 (2725)
Phase 2 (4720)
Phase 3 (5082)
Pipeline (3756)
Policy (29)
Postmarket research (479)
Preclinical (850)
Press Release (6)
Prostate cancer (79)
Psychedelics (11)
Radiopharmaceuticals (58)
Rare diseases (223)
Real estate (485)
Recruiting (5)
Regulatory (3784)
Reports (21)
Research institute (282)
Resumes & cover letters (19)
Rett syndrome (15)
RNA editing (4)
RSV (29)
Schizophrenia (33)
Series A (32)
Series B (19)
Sickle cell disease (29)
Special edition (10)
Spinal muscular atrophy (31)
Sponsored (5)
Startups (290)
Stomach cancer (2)
Supply chain (11)
Switzerland (1)
Tariffs (17)
The Weekly (12)
Vaccines (163)
Venture capital (18)
Weight loss (111)
Women's health (26)
Worklife (1)
Date
Today (4)
Last 7 days (209)
Last 30 days (508)
Last 365 days (6000)
2026 (4953)
2025 (5968)
2024 (6390)
2023 (7415)
2022 (8131)
2021 (8482)
2020 (7702)
2019 (6440)
2018 (4769)
2017 (4392)
2016 (3362)
2015 (4531)
2014 (3196)
2013 (2330)
2012 (2563)
2011 (2800)
2010 (2617)
Location
Africa (66)
Alabama (11)
Arizona (58)
Arkansas (7)
Asia (6082)
Australia (848)
California (2952)
Canada (836)
China (355)
Colorado (135)
Connecticut (128)
Delaware (154)
Europe (14323)
Florida (390)
Georgia (95)
Hawaii (2)
Idaho (4)
Illinois (251)
India (20)
Indiana (213)
Iowa (3)
Japan (170)
Kansas (29)
Kentucky (9)
Louisiana (17)
Maine (24)
Maryland (313)
Massachusetts (2014)
Michigan (66)
Minnesota (169)
Mississippi (1)
Missouri (27)
Montana (7)
Nebraska (1)
Nevada (26)
New Hampshire (22)
New Jersey (1068)
New Mexico (3)
New York (851)
North Carolina (346)
North Dakota (1)
Northern California (1612)
Ohio (85)
Pennsylvania (612)
Puerto Rico (7)
Rhode Island (6)
South America (139)
South Carolina (5)
Southern California (1141)
Tennessee (48)
Texas (424)
United States (10620)
Utah (77)
Virginia (54)
Washington D.C. (8)
Washington State (246)
Wisconsin (20)
Wyoming (1)
98,315 Results for "23".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
BMS picks Texas for new $2.3B manufacturing campus
Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
August 10, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
23andMe Research Institute Announces Inaugural Scientific Advisory Board
October 13, 2026
·
5 min read
Earnings
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the end of July.
August 5, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Biomerica Announces $2.23 Million Financing
August 27, 2026
·
5 min read
Press Releases
Change in Roche’s Board of Directors - September 23, 2026
September 23, 2026
·
1 min read
Press Releases
23andMe Research Institute to Showcase Scientific Impact and Expanded Research Capabilities at ASHG 2026
October 19, 2026
·
2 min read
Immunology and inflammation
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.
October 23, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
October 23, 2026
·
6 min read
C-suite
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
Novo has “gone shopping” to fill pipeline gaps, with a focus on obesity and diabetes, plus an expansion in blood and endocrine disorders, liver diseases and cardiovascular conditions.
September 21, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
September 15, 2026
·
5 min read
1 of 9,832
Next
